Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6601904 | 0.89 | HSD17B10 (0.53) | HSD17B10TARBP2POLBTP53LMNA | |
| SCHEMBL1436227 | 0.78 | HSD17B10 (0.54) | HSD17B10TARBP2POLBTP53LMNA | |
| SCHEMBL6293717 | 0.78 | PPARG (0.50) | HSD17B10TARBP2POLBTP53LMNA | |
| SCHEMBL6810525 | 0.77 | PPARG (0.53) | PPARAPPARGMAPT | |
| SCHEMBL6289197 | 0.77 | PPARG (0.51) | POLBTP53PPARAPPARG | |
| SCHEMBL13179907 | 0.76 | HSD17B10 (0.58) | HSD17B10TARBP2POLBTP53LMNA | |
| SCHEMBL5124569 | 0.76 | LMNA (0.51) | HSD17B10POLBTP53LMNAPPARA | |
| SCHEMBL6293798 | 0.76 | PPARA (0.53) | PPARAPPARG | |
| SCHEMBL3578702 | 0.76 | PPARG (0.55) | TARBP2POLBTP53PPARAPPARG | |
| SCHEMBL5540874 | 0.76 | PPARA (0.53) | HSD17B10TARBP2POLBTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6872732-B2 | Heterocyclic derivatives and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2005-03-29 | — | — | US | disclosed |
| US-20040180924-A1 | Novel heterocyclic derivatives and medicinal use thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180924-A1 | Novel heterocyclic derivatives and medicinal use thereof | GPR119, INSR, GLP1R | HSD17B10 412/4885TARBP2 4865/4885POLB 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.